RE:$10 mil. Annual commitment Toronto, Ontario--(Newsfile Corp. - June 28, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has secured an exclusive US distributor, a Nashville, Tennessee based organization, DME Authority for Therma's patented FDA approved Venowave,a lightweight Deep Vein Thrombosis (DVT) prophylaxisdevice. The multi-year agreement provides Therma Bright with a $10 Million annual minimum purchase commitment, with the initial signing order of 5,000 units coming at a time when competitive mobile DVT prevention devices of the same product category are scarce, on back-order, or indefinitely unavailable in the US due to chip manufacturer shortages similarly affecting many other major industries.